Predictors of coronary artery disease in the Lebanese population

Thrombosis Research

Volumn 117, Issue 6, 2006, Pages 631-637

  Abchee, Antoine ^a   Puzantian, Houry ^a   Azar, Sami T ^a   Shbaklo, Hadia ^a   Nasrallah, Antoine ^a   Sawaya, Fadi J ^a   Alam, Samir ^a   Zalloua, Pierre A ^a,b  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Coronary artery disease; Fasting blood glucose; Lipoprotein (a)

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HOMOCYSTEINE; LIPOPROTEIN A; URIC ACID;

ADULT; AGE DISTRIBUTION; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; LEBANON; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; URIC ACID BLOOD LEVEL;

AGED; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; FASTING; FEMALE; HUMANS; LEBANON; LIPOPROTEIN(A); MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 33646075437     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2005.05.022     Document Type: Article

References (41)

1. Refsum H., Ueland P.M., Nygard O., and Vollset S.E. Homocysteine and cardiovascular disease. Annu Rev Med 49 (1998) 31-62
2. Boushey C.J., Beresford S.A., Omenn G.S., and Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274 (1995) 1049-1057
3. Anderson J.L., Carlquist J.F., Muhlestein J.B., Horne B.D., and Elmer S.P. Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction. J Am Coll Cardiol 32 (1998) 35-41
4. Albert M.A., and Ridker P.M. Inflammatory biomarkers in African Americans: a potential link to accelerated atherosclerosis. Rev Cardiovasc Med 5 Suppl 3 (2004) S22-S27
5. Rohde L.E., Hennekens C.H., and Ridker P.M. Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am J Cardiol 84 (1999) 1018-1022
6. Dangas G, Ambrose JA, D'Agate DJ, Shao JH, Chockalingham S, Levine D. et al., Correlation of serum lipoprotein(a) with the angiographic and clinical presentation of coronary artery disease, Am J Cardiol 1999;83:583-85. A7.
7. Schwartzman R.A., Cox I.D., Poloniecki J., Crook R., Seymour C.A., and Kaski J.C. Elevated plasma lipoprotein(a) is associated with coronary artery disease in patients with chronic stable angina pectoris. J Am Coll Cardiol 31 (1998) 1260-1266
8. Kostner G.M., Avogaro P., Cazzolato G., Marth E., Bittolo-Bon G., and Qunici G.B. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis 38 (1981) 51-61
9. Brand F.N., McGee D.L., Kannel W.B., Stokes III J., and Castelli W.P. Hyperuricemia as a risk factor of coronary heart disease: the Framingham Study. Am J Epidemiol 121 (1985) 11-18
10. Freedman D.S., Williamson D.F., Gunter E.W., and Byers T. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 141 (1995) 637-644
11. Wannamethee S.G., Shaper A.G., and Whincup P.H. Serum urate and the risk of major coronary heart disease events. Heart 78 (1997) 147-153
12. Bickel C., Rupprecht H.J., Blankenberg S., Rippin G., Hafner G., Daunhauer A., et al. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 89 (2002) 12-17
13. Bhopal R., Unwin N., White M., Yallop J., Walker L., Alberti K.G., et al. Heterogeneity of coronary heart disease risk factors in Indian, Pakistani, Bangladeshi, and European origin populations: cross sectional study. BMJ 319 (1999) 215-520
14. Corella D., and Ordovas J.M. The metabolic syndrome: a crossroad for genotype-phenotype associations in atherosclerosis. Curr Atheroscler Rep 6 (2004) 186-196
15. Watson K.E., and Topol E.J. Pathobiology of atherosclerosis: are there racial and ethnic differences?. Rev Cardiovasc Med 5 Suppl. 3 (2004) S14-S21
16. Acarturk E., Cayli M., Akpinar O., Attila G., and Demir M. Relation between age and gender differences in plasma triglyceride concentrations and coronary artery disease in Southern Turkey. Clin Chim Acta 339 (2004) 123-128
17. Luc G., Bard J.M., Ferrieres J., Evans A., Amouyel P., Arveiler D., et al. Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arterioscler Thromb Vasc Biol 22 (2002) 1155-1161
18. Parra H.J., Arveiler D., Evans A.E., Cambou J.P., Amouyel P., Bingham A., et al. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM Study. Arterioscler Thromb 12 (1992) 701-707
19. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 89 (1994) 1333-1445
20. Aydenian H., Fadel M.A., and Baddoura R. Epidemiological study of hyperlipemia in a Lebanese population. Ann Biol Clin (Paris) 57 (1999) 697-703
21. Sibai A.M., Hwalla N., Adra N., and Rahal B. Prevalence and covariates of obesity in Lebanon: findings from the first epidemiological study. Obes Res 11 (2003) 1353-1361
22. Israelsson B., Brattstrom L.E., and Hultberg B.L. Homocysteine and myocardial infarction. Atherosclerosis 71 (1988) 227-233
23. Ubbink J.B., Vermaak W.J., Bennett J.M., Becker P.J., van Staden D.A., and Bissbort S. The prevalence of homocysteinemia and hypercholesterolemia in angiographically defined coronary heart disease. Klin Wochenschr 69 (1991) 527-534
24. Wilcken D.E., Reddy S.G., and Gupta V.J. Homocysteinemia, ischemic heart disease, and the carrier state for homocystinuria. Metabolism 32 (1983) 363-370
25. Antonio C.M., Nunes M.C., Refsum H., and Abraham AK. A novel pathway for the conversion of homocysteine to methionine in eukaryotes. Biochem J 328 Pt 1 (1997) 165-170
26. Cooke J.P., and Dzau V.J. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 48 (1997) 489-509
27. Durand P., Prost M., Loreau N., Lussier-Cacan S., and Blache D. Impaired homocysteine metabolism and atherothrombotic disease. Lab Invest 81 (2001) 645-672
28. Upchurch Jr. G.R., Welch G.N., Fabian A.J., Freedman J.E., Johnson J.L., Keaney Jr. J.F., et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 272 (1997) 17012-17017
29. Boufidou A.I., Makedou A.D., Adamidis D.N., Karvounis H.I., Gourassas J.T., Kesidis H.T., et al. Parharidis Association between plasma homocysteine levels and coronary artery disease: a population-based study in northern Greece. Curr Med Res Opin 20 (2004) 175-180
30. Danesh J., Collins R., and Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 102 (2000) 1082-1085
31. Gazzaruso C., Garzaniti A., Falcone C., Geroldi D., Finardi G., and Fratino P. Association of lipoprotein(a) levels and apolipoprotein(a) phenotypes with coronary artery disease in Type 2 diabetic patients and in non-diabetic subjects. Diabet Med 18 (2001) 589-594
32. Paultre F., Pearson T.A., Weil H.F., Tuck C.H., Myerson M., Rubin J., et al. High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men. Arterioscler Thromb Vasc Biol 20 (2000) 2619-2624
33. Gazzaruso C., Garzaniti A., Giordanetti S., Falcone C., and Fratino P. Silent coronary artery disease in type 2 diabetes mellitus: the role of Lipoprotein(a), homocysteine and apo(a) polymorphism. Cardiovasc Diabetol 1 (2002) 5
34. Ruiz J., Thillet J., Huby T., James R.W., Erlich D., Flandre P., et al. Association of elevated lipoprotein(a) levels and coronary heart disease in NIDDM patients. Relationship with apolipoprotein(a) phenotypes. Diabetologia 37 (1994) 585-591
35. Milan Study on Atherosclerosis and Diabetes (MiSAD) Group. Prevalence of unrecognized silent myocardial ischemia and its association with atherosclerotic risk factors in noninsulin-dependent diabetes mellitus. Am J Cardiol 79 (1997) 134-139
36. American Diabetes Association. Consensus development conference on the diagnosis of coronary heart disease in people with diabetes: 10-11 February 1998, Miami, Florida. Diabetes Care 21 (1998) 1551-1559
37. Weiner D.A., Ryan T.J., Parsons L., Fisher L.D., Chaitman B.R., Sheffield L.T., et al. Significance of silent myocardial ischemia during exercise testing in patients with diabetes mellitus: a report from the Coronary Artery Surgery Study (CASS) Registry. Am J Cardiol 68 (1991) 729-734
38. Kukreja N., Wilkinson J.R., MacDuff A., Galloway C.F., and Fox K.M. Under-diagnosis of diabetes mellitus in patients with coronary artery disease. Int J Cardiol 97 (2004) 77-82
39. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20 (1997) 1183-1197
40. Haffner S.M., Stern M.P., Hazuda H.P., Mitchell B.D., and Patterson J.K. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?. JAMA 263 (1990) 2893-2898
41. Haffner S.M., Mykkanen L., Festa A., Burke J.P., and Stern M.P. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 101 (2000) 975-980